Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Sossalla

Showing results (11-20 of 296) with videos related to

Pageof 30
Sort By:
Pharmacology & Therapeutics|December 3, 2011
Role of ranolazine in angina, heart failure, arrhythmias, and diabetesSamuel Sossalla, Lars S Maier
Journal of Cardiovascular Pharmacology and Therapeutics|May 1, 2016
The Significance of the Late Na<sup>+</sup> Current for Arrhythmia Induction and the Therapeutic Antiarrhythmic Potential of RanolazineFleur E Mason, Samuel Sossalla
Kardiologia Polska|December 22, 2009
Young ambitious cardiologists and scientific research - reasons to get involvedSamuel Sossalla, Lars S Maier
European Heart Journal. Cardiovascular Pharmacotherapy|December 24, 2024
The untapped potential of guideline-directed heart failure pharmacotherapy: consequences of missed opportunitiesEster J Herrmann, Samuel Sossalla
Circulation Research|January 20, 2022
Neuron-Restrictive Silencer Factor Limits Myocyte Gα<sub>O</sub> Expression and Is Protective in Heart Failure ProgressionSamuel Sossalla, Donald M Bers
Kardiologia Polska|January 8, 2010
Scientific teamwork--a particular approachSamuel Sossalla, Jan D Schmitto
European Journal of Heart Failure|December 30, 2020
A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'Steffen Pabel, Nazha Hamdani, Samuel Sossalla
European Heart Journal. Cardiovascular Pharmacotherapy|April 18, 2025
Early initiation of SGLT2 Inhibitors after Acute Myocardial InfarctionAndeas Hammer, Samuel Sossalla, Patrick Sulzgruber
European Heart Journal. Case Reports|August 6, 2024
Case report of persistent atrial fibrillation with durably isolated pulmonary veins: what's next?Philipp Bengel, Samuel Sossalla, Borislav Dinov
Innere Medizin (Heidelberg, Germany)|July 15, 2024
[Oral anticoagulation in supraventricular arrhythmia]Philipp Bengel, Samuel Sossalla, Borislav Dinov
Pageof 30

Showing results (11-20 of 296) with videos related to

Sort By:
Pageof 30
Pharmacology & Therapeutics|December 3, 2011
Role of ranolazine in angina, heart failure, arrhythmias, and diabetesSamuel Sossalla, Lars S Maier
Journal of Cardiovascular Pharmacology and Therapeutics|May 1, 2016
The Significance of the Late Na<sup>+</sup> Current for Arrhythmia Induction and the Therapeutic Antiarrhythmic Potential of RanolazineFleur E Mason, Samuel Sossalla
Kardiologia Polska|December 22, 2009
Young ambitious cardiologists and scientific research - reasons to get involvedSamuel Sossalla, Lars S Maier
European Heart Journal. Cardiovascular Pharmacotherapy|December 24, 2024
The untapped potential of guideline-directed heart failure pharmacotherapy: consequences of missed opportunitiesEster J Herrmann, Samuel Sossalla
Circulation Research|January 20, 2022
Neuron-Restrictive Silencer Factor Limits Myocyte Gα<sub>O</sub> Expression and Is Protective in Heart Failure ProgressionSamuel Sossalla, Donald M Bers
Kardiologia Polska|January 8, 2010
Scientific teamwork--a particular approachSamuel Sossalla, Jan D Schmitto
European Journal of Heart Failure|December 30, 2020
A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'Steffen Pabel, Nazha Hamdani, Samuel Sossalla
European Heart Journal. Cardiovascular Pharmacotherapy|April 18, 2025
Early initiation of SGLT2 Inhibitors after Acute Myocardial InfarctionAndeas Hammer, Samuel Sossalla, Patrick Sulzgruber
European Heart Journal. Case Reports|August 6, 2024
Case report of persistent atrial fibrillation with durably isolated pulmonary veins: what's next?Philipp Bengel, Samuel Sossalla, Borislav Dinov
Innere Medizin (Heidelberg, Germany)|July 15, 2024
[Oral anticoagulation in supraventricular arrhythmia]Philipp Bengel, Samuel Sossalla, Borislav Dinov
Pageof 30